Search
human chorionic gonadotropin (APL, hCG)
Tradename: A.P.L.
Indications:
1) induction of ovulation & pregnancy
2) treatment of hypogonadotropic hypogonadism
3) prepubertal cryptorchism
Dosage:
1) prepubertal cryptorchidism:
- 1000 to 2000 units/m2 IV 3 times/week for 3 weeks
2) hypogonadotropic hypogonadism
a) 500-1000 units/m2 IV 3 times/week for 3 weeks, then
b) 500-1000 units/m2 IV 2 times/week for 3 weeks
Powder for injection:
a) 500, 1000 & 2000 units/mL (10 mL)
b) human origin
Adverse effects:
1) not common (1-10%)
- pelvic pain, ovarian cysts, breast enlargement, precocious puberty, pain at the injection site, depression, tiredness, premature closure of epiphysis
2) uncommon (< 1%)
- peripheral edema, ovarian hyperstimulation, irritability, restlessness, fatigue, headache, gynecomastia
Notes:
- expressed by syncytiotrophoblastic cells of the placenta during pregnancy [2]
Related
Lutropin-choriogonadotropic hormone receptor; LH/CG-R; LSH-R; Luteinizing hormone receptor; LHR (LHCGR, LCGR, LGR2 LHRHR)
General
chorionic gonadotropin; choriogonadotropin (APL, hCG)
endocrine agent
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Betz D, Fane K
Human Chorionic Gonadotropin
StatPearls [Internet]. NLM. August 14, 2023
https://www.ncbi.nlm.nih.gov/books/NBK532950/